menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Ex-Theseus execs extend GIST mission by taking helm of IDRx

    ENDPTS

    Theseus Pharmaceuticals Announces Closing of Tender Offer

    PR NEWSWIRE

    Concentra scores another win as Theseus agrees to buyout offer

    FIERCE BIOTECH

    Theseus Confirms Receipt of Expression of Interest from Foresite Capital

    PR NEWSWIRE

    Months after ending cancer program, Theseus lays off 72%

    FIERCE BIOTECH

    Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives

    PRESS RELEASE

    Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference

    PR NEWSWIRE

    Theseus to Discontinue Enrollment in Ph 1/2 & Terminate Development of THE-630

    PR NEWSWIRE

    Theseus Reports Initial Dose Escalation Data from Phase 1/2 Trial of THE-630

    PR NEWSWIRE

    Theseus Pharmaceuticals Announces Business Highlights and Reports 1Q 2023 FYR

    PR NEWSWIRE

    Theseus Initial Dose Escalation Results from Ongoing Ph 1/2 Trial of THE-630

    PR NEWSWIRE

    Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences

    PR NEWSWIRE

    Theseus to Participate in the Cantor Future of Oncology Virtual Symposium

    PR NEWSWIRE

    Theseus Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

    PR NEWSWIRE

    Theseus to Participate in the SVB Securities Global Biopharma Conference

    PRESS RELEASE

    Theseus Announces BCR-ABL as Target for Third Development Program

    PRESS RELEASE

    Theseus Announces Business and Reports Third Quarter 2022 Financial Results

    PRESS RELEASE

    Theseus Pharmaceuticals Reports Third Quarter 2022 Financial Results

    PRESS RELEASE

    Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349

    PRNEWSWIRE

    Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors

    PRNEWSWIRE

    Theseus Pharmaceuticals Nominates THE-349

    PRNEWSWIRE

    Theseus Pharma to Participate at Upcoming September Investor Conferences

    PRNEWSWIRE

    Theseus Pharma to Participate Virtually in Wedbush PacGrow Healthcare Conference

    PRNEWSWIRE

    Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences

    PRNEWSWIRE

    Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

    PRNEWSWIRE

    Theseus Pharma Reports First Quarter 2022 Financial Results

    PRNEWSWIRE

    Theseus Pharma Announces PC Data on EGFR Inhibitors at the 2022 AACR

    PRNEWSWIRE

    Theseus Pharma to Participate Virtually in Needham Healthcare Conference

    PRNEWSWIRE

    Vipergen Establishes DEL-Based Drug Discovery Partnership with Theseus Pharma

    PRNEWSWIRE

    Theseus Pharma Reports Fourth Quarter and Full Year 2021 Financial Results

    PRNEWSWIRE

    Theseus Pharma to Present PC Data on Next-Gen EGFR Inhibitors at 2022 AACR

    PRNEWSWIRE

    Theseus Pharma Receives U.S. FDA ODD for THE-630 for Advanced GIST

    PRNEWSWIRE

    Theseus Pharma Treats First Patient with THE-630 in Phase 1/2 Study in GIST

    PRNEWSWIRE

    Theseus Pharma Appoints Alicja Januszewicz as Senior Vice President

    PRESS RELEASE

    Theseus Announces Business Highlights and Reports Q3 2021 Financial Results

    PRNEWSWIRE

    Theseus Announces FDA Clearance of INDA for THE-630

    PRNEWSWIRE

    Theseus stock pops 53% intraday following cancer-drug firm’s upsized IPO

    SEEKINGALPHA

    OrbiMed`s TKI play makes its Nasdaq debut as Theseus prices IPO

    ENDPTS

    Theseus Pharmaceuticals Announces Pricing of Initial Public Offering

    PRNEWSWIRE

    Solid tumor biotech Theseus Pharmaceuticals files for a $100 million IPO

    RENAISSANCECAPITAL

    Theseus Appoints Kathy Yi to Board of Directors and Chair of Audit Committee

    PRNEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.